Targeted radionuclide detection of malignant tumors using affibody

This review examines the potential applications of affibody molecules in various fields of biotechnology and clinical medicine. Consideration is given to the high affinity and specificity of affibody molecules for selected molecular targets, as well as their potential for the in vivo visualization of various malignant tumors. Significant attention is paid to preclinical and clinical studies of affibody conjugates with various radioisotopes for targeted radionuclide tumor imaging, which is particularly relevant in addressing challenges encountered during the diagnosis and treatment of these patients. Clinical trials demonstrate that radiopharmaceuticals are well-tolerated and effective for the assessment of tumor process prevalence and the determination of HER2/neu status in breast cancer patients, supporting further research.

Authors

Institutions

Publication Details

Journal
Acta Naturae
Published
2025-12-04
DOI
https://doi.org/10.32607/actanaturae.27677
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeted radionuclide detection of malignant tumors using affibody

О.А. Bragina, Sergey M. Deyev, Ekaterina Yu. Sitnikova, Stanislav V. Patalyak et al.
Acta Naturae
Monoclonal and Polyclonal Antibodies Research
article

Targeted radionuclide detection of malignant tumors using affibody

О.А. Bragina, Sergey M. Deyev, Ekaterina Yu. Sitnikova, Stanislav V. Patalyak, Alexander A. Nesynov
article en

Abstract

This review examines the potential applications of affibody molecules in various fields of biotechnology and clinical medicine. Consideration is given to the high affinity and specificity of affibody molecules for selected molecular targets, as well as their potential for the in vivo visualization of various malignant tumors. Significant attention is paid to preclinical and clinical studies of affibody conjugates with various radioisotopes for targeted radionuclide tumor imaging, which is particularly relevant in addressing challenges encountered during the diagnosis and treatment of these patients. Clinical trials demonstrate that radiopharmaceuticals are well-tolerated and effective for the assessment of tumor process prevalence and the determination of HER2/neu status in breast cancer patients, supporting further research.

Acta NaturaeVol. 17(4)
National Research Tomsk State University (RU), Siberian State Medical University (RU), Tomsk Polytechnic University (RU), Institute of Bioorganic Chemistry (RU), Tomsk Cancer Research Institute (RU)
Good health and well-being
Openalex Percentile: Top 31%
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.